Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase 2 Clinical Trial of an Anti-Androgen and A 5-Alpha Reductase Inh-261075017
Mayo Foundation
Search grants from Mayo Foundation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Persistence of WNV RNA in blood and the risk of transfusion-transmission
R01-Proteomic characterization of alternate splicing and cSNP protein isoforms
SBIR Phase I: Bandgap-Uniform Semiconducting Carbon Nanotubes for Thin Film Transistors
Versatile Modeling of Smart Materials Performance in Infrastructure Applications via Distributed Hysterons
Rujm el-Hiri: A Megalithic Monument from the Southern Levant
Recently added grants:
Algorithms to link signaling pathways with transcriptional programs for precision medicine
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
ADAPT+: Optimizing an Intervention to Promote Healthy Behaviors in Rural, Latino Youth with Obesity and their Parents, using Mindfulness Strategies
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
Elucidate the mechanism of autophagy in supporting Lkb1-deficient lung tumorigenesis and metastasis
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075017-008
Application #
7329467
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2006
Total Cost
Indirect Cost
Institution
Name
Mayo Foundation
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2006
N01 CA
Phase 2 Clinical Trial of an Anti-Androgen and A 5-Alpha Reductase Inh-261075017
/ Mayo Foundation
NIH 2003
N01 CA
Phase 2 Clinical Trial of an Anti-Androgen and A 5-Alpha Reductase Inh-261975017
/ Mayo Foundation
Comments
Be the first to comment on this grant